Heartflow (HTFL) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Heartflow insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1.1M and 6 sold $138M of HTFL stock on the open market.
Get emailed when insiders cluster-buy stocks like HTFL
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
HTFL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $13.1M | 18 |
| Q2 2026 | — | 0 | $64.0M | 10 |
| Q1 2026 | — | 0 | $61.0M | 8 |
| Q4 2025 | $1.1M | 1 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Heartflow, Inc. insider reported open-market purchases totaling $1.1M, while 6 insiders reported sales totaling $138M. 31 of 36 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 21SEC | Campbell RogersChief Medical Officer | Sell Plan | 19,68279,956 held (−20%) | $50.15 | $987K | -0.8% | — |
| Sep 18SEC | Vikram VergheseCFO | Sell Plan | 16,766155,183 held (−10%) | $50.75 | $851K | -2.0% | — |
| Sep 18SEC | Vikram VergheseCFO | Sell Plan | 7,579171,949 held (−4%) | $50.11 | $380K | -0.7% | — |
| Sep 15SEC | Vikram VergheseCFO | Sell Plan | 29,714184,789 held (−14%) | $50.06 | $1.5M | -0.6% | — |
| Sep 15SEC | Vikram VergheseCFO | Sell Plan | 4,593180,196 held (−2%) | $50.24 | $231K | -1.0% | — |
| Sep 15SEC | Vikram VergheseCFO | Sell Plan | 668179,528 held (−0%) | $50.01 | $33K | -0.5% | — |
| Sep 14SEC | John C.m. FarquharCEO | Sell Plan | 35,010325,804 held (−10%) | $46.42 | $1.6M | +7.2% | — |
| Sep 14SEC | John C.m. FarquharCEO | Sell Plan | 3,890321,914 held (−1%) | $50.00 | $194K | -0.5% | — |
| Sep 10SEC | Vikram VergheseCFO | Sell Plan | 6,640214,503 held (−3%) | $50.03 | $332K | -0.6% | — |
| Sep 4SEC | Vikram VergheseCFO | Sell Plan | 27,540221,143 held (−11%) | $49.69 | $1.4M | +0.1% | — |
| Sep 4SEC | Vikram VergheseCFO | Sell Plan | 5,876248,683 held (−2%) | $50.60 | $297K | -1.7% | — |
| Aug 25SEC | John C.m. FarquharCEO | Sell Plan | 27,230360,814 held (−7%) | $50.00 | $1.4M | -0.5% | — |
| Aug 20SEC | John C.m. FarquharCEO | Sell Plan | 32,676388,044 held (−8%) | $45.00 | $1.5M | +10.5% | — |
| Aug 19SEC | Campbell RogersChief Medical Officer | Sell Plan | 9,21986,459 held (−10%) | $41.23 | $380K | +20.6% | — |
| Aug 18SEC | John C.m. FarquharCEO | Sell Plan | 15,560420,720 held (−4%) | $39.06 | $608K | +27.3% | — |
| Aug 12SEC | John C.m. FarquharCEO | Sell Plan | 22,562436,280 held (−5%) | $28.31 | $639K | +75.7% | — |
| Jul 17SEC | Campbell RogersChief Medical Officer | Sell Plan | 9,21988,731 held (−9%) | $25.72 | $237K | +93.4% | — |
| Jul 13SEC | John C.m. FarquharCEO | Sell Plan | 22,562435,373 held (−5%) | $27.75 | $626K | +79.2% | — |
| Jun 26SEC | John C.m. FarquharCEO | Sell Plan | 38,900457,935 held (−8%) | $35.00 | $1.4M | +42.1% | — |
| Jun 12SEC | John C.m. FarquharCEO | Sell Plan | 22,562496,835 held (−4%) | $28.50 | $643K | +74.5% | — |
| May 20SEC | Campbell RogersChief Medical Officer | Sell Plan | 9,21978,731 held (−10%) | $28.34 | $261K | +75.5% | — |
| May 13SEC | John C.m. FarquharCEO | Sell Plan | 22,562519,397 held (−4%) | $29.12 | $657K | +70.8% | — |
| Apr 30SEC | Bain Capital Life Sciences Iii General Partner, Llc10% Owner | Sell | 892,5338,504,382 held (−9%) | $29.18 | $26.0M | +70.5% | — |
| Apr 30SEC | Bain Capital Life Sciences Iii General Partner, Llc10% Owner | Sell | 797,1339,396,915 held (−8%) | $29.37 | $23.4M | +69.4% | — |
| Apr 30SEC | Bain Capital Life Sciences Iii General Partner, Llc10% Owner | Sell | 254,11010,194,048 held (−2%) | $30.51 | $7.8M | +63.0% | — |
| Apr 30SEC | Bain Capital Life Sciences Iii General Partner, Llc10% Owner | Sell | 56,2248,448,158 held (−1%) | $30.05 | $1.7M | +65.5% | — |
| Apr 14SEC | John C.m. FarquharCEO | Sell Plan | 22,562549,163 held (−4%) | $26.72 | $603K | +86.2% | — |
| Apr 3SEC | Campbell RogersChief Medical Officer | Sell Plan | 64,53381,002 held (−44%) | $24.64 | $1.6M | +101.9% | — |
| Mar 23SEC | Campbell RogersChief Medical Officer | Sell Plan | 64,53378,518 held (−45%) | $25.69 | $1.7M | +93.6% | — |
| Mar 20SEC | John C.m. FarquharCEO | Sell Plan | 9,725571,725 held (−2%) | $25.00 | $243K | +99.0% | — |
| Mar 12SEC | John C.m. FarquharCEO | Sell Plan | 12,837581,450 held (−2%) | $22.66 | $291K | +119.5% | — |
| Mar 6SEC | Julie A CullivanDirector | Sell Plan | 9,12227,291 held (−25%) | $25.00 | $228K | +99.0% | — |
| Feb 17SEC | Campbell RogersChief Medical Officer | Sell Plan | 65,15376,034 held (−46%) | $24.49 | $1.6M | +103.1% | — |
| Feb 10SEC | John C.m. FarquharCEO | Sell Plan | 22,562591,656 held (−4%) | $27.46 | $620K | +81.1% | — |
| Feb 6SEC | Bain Capital Life Sciences Investors, Llc10% Owner | Sell | 2,000,00010,448,158 held (−16%) | $28.05 | $56.1M | +77.3% | — |
| Feb 6SEC | Julie A CullivanDirector | Sell Plan | 8,00036,413 held (−18%) | $27.32 | $219K | +82.1% | — |
| Dec 17SEC | Jeffrey C LightcapDirector | Buy | 40,000new position | $26.34 | $1.1M | +88.8% | — |
Insiders at Heartflow, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Bain Capital Life Sciences Iii General Partner, Llc10% Owner | — | $58.9M | Apr 30, 2026 | — |
| Bain Capital Life Sciences Investors, Llc10% Owner | — | $56.1M | Feb 6, 2026 | — |
| John C.m. FarquharCEO | — | $10.9M | Sep 14, 2026 | — |
| Campbell RogersChief Medical Officer | — | $6.7M | Sep 21, 2026 | — |
| Vikram VergheseCFO | — | $5.0M | Sep 18, 2026 | — |
| Jeffrey C LightcapDirector | $1.1M | — | Dec 17, 2025 | — |
| Julie A CullivanDirector | — | $447K | Mar 6, 2026 | — |
HTFL stock: common questions
Are Heartflow, Inc. insiders buying HTFL stock?
In the past 12 months, 1 insiders reported open-market purchases of HTFL worth $1.1M. The latest was Director Jeffrey C Lightcap bought $1.1M of HTFL at $26.34 — first open-market purchase in our records; opens a new position.
Are Heartflow, Inc. insiders selling HTFL stock?
6 insiders reported sales worth $138M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is HTFL's 52-week range?
Over the past year HTFL has traded between $20.49 and $52.21. It last closed at $49.74 on Oct 9, 2026.